Will the Lack of Efficacious Therapies Open the Door for a New Clinical Gold Standard in Obesity Treatment?

— A Webinar from Decision Resources

Based on our DecisionBase 2010 report entitled Obesity: A Novel Oral Therapy Emerges That Delivers Superior Weight-Loss Efficacy, Decision Resources is offering an exclusive webinar entitled Will the Lack of Efficacious Therapies Open the Door for a New Clinical Gold Standard in Obesity Treatment? Because this webinar will feature major report findings, it is ONLY available to purchasers of this report.

Please contact us to learn how you can purchase this report and attend the webinar.

Over 300 million adults in the world’s major pharmaceutical markets were estimated to be overweight or obese in 2009, and—given the steady rise in the prevalence of childhood obesity—this number is expected to increase substantially over the next decade. The drug-treatment rates for obesity are extremely low compared with those of other common disorders and this is due, in part, to the lack of efficacious, safe, or well-tolerated drug options. The withdrawal of Abbott Laboratories’ Meridia/Reductil in Europe earlier this year highlights the safety issues that have plagued the obesity market ever since Wyeth’s Redux and Pondimin were withdrawn in 1997.

The use of the current clinical gold standard, orlistat (Roche’s Xenical, GlaxoSmithKline’s OTC Alli), is driven by physicians’ confidence in its safety, owing to orlistat’s peripheral mechanism of action. However, orlistat has only moderate weight-loss efficacy and is associated with severe gastrointestinal side effects. As a result, there is great commercial potential for novel therapies that can provide improved efficacy, safety and tolerability.

This webinar, presented by Decision Resources Analyst Kate Sullivan, will answer the following questions:

• Among the novel obesity therapies set to launch in the near-term—which include drugs from Arena Pharmaceuticals, Vivus and Orexigen Therapeutics—what impact do interviewed thought leaders expect these agents to have on the obesity drug market?
• As the benefits offered by emerging therapies over current therapies vary, which drug attributes have the greatest impact on physician prescribing decisions for obesity?
• What are the greatest areas of unmet need in obesity, according to prescribers, and which emerging therapies are most likely to address these unmet needs?
• According to surveyed U.S. physicians, which current agents are most likely to be replaced by emerging therapies and what percentage of patient share is each therapy likely to attain?

Ms. Sullivan will conduct a live Q & A session after the presentation.

Registration

Will the Lack of Efficacious Therapies Open the Door for a New Clinical Gold Standard in Obesity Treatment?

March 17, 2010 at 10 a.m. U.S. Eastern Time, 3 p.m. Central European Time (Paris).

To learn how you can purchase this report and attend the webinar, please contact us using the information below.

Contact Us

In North America — Keith Rourke at 781-296-2656 or krourke@dresources.com

In Europe — Kaj van Langendonck at +32-2-357-06-14 or kvanlangendonck@decisionresources.be

In Japan — Makiko Yoshimoto at +81-3-5401-2615 or makiko@dresources.jp

Terms of Use | Privacy Policy | Contact Us | Careers

Decision Resources • 260 Charles Street • Waltham, MA 02453

Register to receive our latest offers. You are receiving this email because you have previously requested information from Decision Resources.

© 2010 Decision Resources, Inc. All rights reserved.